Bo sheng ji medicine science and technology (suzhou) co., LTD
博生吉
Bo sheng ji medicine science and technology (suzhou) co., LTD
Biotech/Healthcare
PersonGen BioTherapeutics develops technologies and products for cancer cell immunotherapy. Its primary focus is the development of tumor cell immunotherapy technologies and products, with clinical technical services as its main business.
Latest round: Series C Extension (2026)
Source: ChinaBulls — chinabulls.com
Last updated 2026-06-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.